GUTS - NASDAQ
Fractyl Health, Inc. Common Stock
$0.79
+0.66%Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
At a Glance
Live SnapshotFractyl Health, Inc. Common Stock Profit Bridge
Profitability Analysis
Fractyl Health, Inc. Common Stock Income Statement
GUTS • NASDAQ
| Fractyl Health, Inc. Common Stock Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
0.0 | 93K | 120K | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(1.1M) | (50K) | (77K) | (452K) | (0.0) | (770K) | (893K) | |
-1.1M | 43K | 43K | -452K | 0.0 | -770K | -893K | |
OPERATING INCOME | |||||||
(95.7M) | (93.6M) | (50.9M) | (48.9M) | (36.9M) | (28.2M) | (29M) | |
(21.2M) | (0.0) | (0.0) | (14.6M) | (10.5M) | (5.8M) | (8.1M) | |
(74.5M) | (70.5M) | (38M) | (34.4M) | (26.4M) | (22.4M) | (20.9M) | |
-96.8M | -93.5M | -50.8M | -49.4M | -36.9M | -29M | -29.9M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (1.4M) | (1.5M) | (635K) | |
1.5M | 4.1M | 1.3M | 797K | -1.4M | -1.5M | 0.0 | |
(0.0) | (23.1M) | (12.8M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-44.1M | 24.8M | -26.3M | 2.9M | -1.8M | -1.5M | -673K | |
-141M | -68.7M | -77.1M | -46.5M | -38.7M | -30.5M | -30.6M | |
NET INCOME | |||||||
-141M | -68.7M | -77.1M | -46.5M | -38.7M | -30.5M | -30.6M |
SEC Filings
GUTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 06, 2026 | December 30, 2025 | 2025 |
Related Guides
Continue your GUTS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.